DUX4 Expression is Prevalent in Metastatic Cancers and Predicts Poor Response to Immune Checkpoint Inhibition
DUX4 expression is a common feature of diverse metastatic cancers, where it suppresses anti-tumor immunity and is associated with decreased response and survival in patients treated with immune checkpoint inhibitors.